10Elms LLP Purchases Shares of 2,613 Pfizer Inc. (NYSE:PFE)

10Elms LLP purchased a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel reports. The fund purchased 2,613 shares of the biopharmaceutical company’s stock, valued at approximately $69,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Up 2.2%

Shares of NYSE:PFE opened at $23.51 on Wednesday. The stock has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The stock’s 50-day moving average price is $23.56 and its 200-day moving average price is $25.27. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company earned $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.